Ian S Dayes

McMaster University

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Medical Imaging Medical Imaging professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (29)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (10)

Stefanie Hayoz

Head of Statistics

SWITZERLAND

View details

Sameer Parpia

Associate Professor & Biostatistician

McMaster University

CANADA

View details

Theodoros Tsakiridis

CANADA

View details

Pamela Coleman

Associate Professor of Surgery

Howard University

UNITED STATES

View details

Andrea Eisen

McMaster University

CANADA

View details

Robert Dess

University of Michigan

UNITED STATES

View details

Ann Henry

Associate Professor in Clinical Oncology

University of Leeds School of Medicine

UNITED KINGDOM

View details

Mark N. Levine

McMaster University

CANADA

View details

Anand Swaminath

juravinski cancer centre mcmaster university hamilton ontario canada

CANADA

View details

Timothy J Whelan

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ian S Dayes

Research Interests

Explore related searches

Contact this professor

Articles (29)

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.

18F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc Analysis.

Long term results of NRG Oncology RTOG 9601, a randomized trial of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy post prostatectomy

In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable‐Intermediate and High‐Risk Prostate Cancer

Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable‐Intermediate and High‐Risk Prostate Cancer

Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer

Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.

PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126.

The prognostic impact of prostate-specific antigen at 6 months after post-prostatectomy radiotherapy: An individual patient data analysis of two NRG oncology randomized trials.

Patterns of failure with 18F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting: A regional cohort analysis

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer

Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.

Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers

Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer

Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer

Low-Dose Hemibody Radiation, a Treatment Option for Recurrent Prostate Cancer: A Phase 2 Single-Arm Trial

Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

Genomic classifier performance in intermediate-risk prostate cancer: Results from NRG Oncology/RTOG 0126 randomized phase III trial

Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415

Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.

Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with 18 F-DCFPyL PSMA-PET: A regional cohort analysis.

Patterns of failure with 18 F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.

Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC)

Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer

114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Collaborators (10)

Stefanie Hayoz

Sameer Parpia

Theodoros Tsakiridis

Pamela Coleman

Andrea Eisen

Robert Dess

Ann Henry

Mark N. Levine

Anand Swaminath

Timothy J Whelan

Make your next move.